company background image
GLS

Gelesis Holdings NYSE:GLS Stock Report

Last Price

US$0.38

Market Cap

US$28.0m

7D

-1.6%

1Y

-96.1%

Updated

27 Nov, 2022

Data

Company Financials +
GLS fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health1/6
Dividends0/6

GLS Stock Overview

Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases.

Gelesis Holdings, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Gelesis Holdings
Historical stock prices
Current Share PriceUS$0.38
52 Week HighUS$12.23
52 Week LowUS$0.24
Beta0.85
1 Month Change4.01%
3 Month Change-68.80%
1 Year Change-96.14%
3 Year Changen/a
5 Year Changen/a
Change since IPO-96.10%

Recent News & Updates

Gelesis Holdings GAAP EPS of -$0.20, revenue of $6.65M

Nov 14

Recent updates

Shareholder Returns

GLSUS BiotechsUS Market
7D-1.6%0.4%1.3%
1Y-96.1%-14.4%-18.5%

Return vs Industry: GLS underperformed the US Biotechs industry which returned -14.4% over the past year.

Return vs Market: GLS underperformed the US Market which returned -18.5% over the past year.

Price Volatility

Is GLS's price volatile compared to industry and market?
GLS volatility
GLS Average Weekly Movement22.4%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: GLS is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 22% a week.

Volatility Over Time: GLS's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2006101Yishai Zoharhttps://www.gelesis.com

Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation.

Gelesis Holdings, Inc. Fundamentals Summary

How do Gelesis Holdings's earnings and revenue compare to its market cap?
GLS fundamental statistics
Market CapUS$28.03m
Earnings (TTM)-US$44.83m
Revenue (TTM)US$26.03m

1.1x

P/S Ratio

-0.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GLS income statement (TTM)
RevenueUS$26.03m
Cost of RevenueUS$15.71m
Gross ProfitUS$10.32m
Other ExpensesUS$55.15m
Earnings-US$44.83m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.61
Gross Margin39.63%
Net Profit Margin-172.23%
Debt/Equity Ratio825.9%

How did GLS perform over the long term?

See historical performance and comparison